VALSARTAN | N020665 | NOVARTIS PHARMACEUTICALS CORP
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 4 | Not Yet Recruiting | Kyungsub Song | 80 | 2026-06-30 → 2029-12-30 | |
| Phase 4 | Recruiting | Martin Rohacek | 298 | 2026-06-30 → 2028-11-30 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Total Spending
$23.8M
Total Claims
29,222
Beneficiaries
6,468
Avg Cost/Unit
$10.09
Spending Trend
Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.
28 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Feb 7, 2017 | SUPPL -39 | View Letter (PDF) |
| Jul 28, 2015 | SUPPL -38 | View Letter (PDF) |
| Sep 26, 2014 | SUPPL -37 | View Letter (PDF) |
| Mar 19, 2014 | SUPPL -34 | View Letter (PDF) |
| Mar 19, 2014 | SUPPL -35 | View Letter (PDF) |
| Oct 30, 2013 | SUPPL -33 | View Letter (PDF) |
| Aug 14, 2002 | SUPPL -16 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.